Dana-Farber leads adaptive, efficient multi-arm phase 2 clinical trial for glioblastoma
EMBARGOED: September 18, 2023 4PM EST
CONTACT: Nicole Oliverio, nicole_oliverio@dfci.harvard.edu, 617-257-0454
Boston – An innovative phase 2 clinical trial led by Dana-Farber Cancer Institute in collaboration with 10 major brain tumor centers around the country and designed to find new potential treatments for glioblastoma has reported initial results in the Journal of Clinical Oncology. While none of the three therapeutics tested so far improved overall survival of patients, this adaptive platform trial, the first of its kind in neuro-oncology, has the potential to rapidly and efficiently identify therapies that ...














